Sustainable Development Goals and the Future of Cardiovascular Health: A Statement From the Global Cardiovascular Disease Taskforce

Zoghbi, William A.; Duncan, Tony; Antman, Elliott M.; Barbosa, Marcia; Champagne, Beatriz; Chen, Deborah; Gamra, Habib; Harold, John; Josephson, Staffan; Komajda, Michel; Løgstrup, Susanne; Mayosi, Bongani M.; Mwangi, Jeremiah; Ralston, Johanna; Sacco, Ralph L.; Sim, Kui Hian; Smith, Sidney C.; Vardas, Panos; Wood, David

doi:10.1161/jaha.114.000504

Cited by 35 publications

(24 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Global Cardiovascular Disease Taskforce, comprising the World Heart Federation, American Heart Association, American College of Cardiology Foundation, European Heart Network, and European Society of Cardiology, with expanded representation from Asia, Africa, and Latin America, along with global CVD experts, disseminates information and approaches to reach the WHO 2025 targets. [2][3][4] To achieve the overarching 25 by 25 target, the WHO identified 8 targets in the prevention, control, and treatment of 6 key risk factors, as well as 2 health systems targets related to the use of essential medicines, technologies, and drug therapies, to prevent NCDs, particularly CVDs. 5 Of the 8 targets, 6 directly align with traditional CVD and stroke risk factors: 3 risk factors (tobacco use, sodium intake, physical inactivity), 2 biological risk factors (raised blood pressure [BP], DM/obesity), and 1 management target directed at the treatment of individuals at high risk of CVD.…”

mentioning

confidence: 99%

The Heart of 25 by 25: Achieving the Goal of Reducing Global and Regional Premature Deaths From Cardiovascular Diseases and Stroke

Sacco¹,

Roth²,

Reddy³

et al. 2016

Circulation

Self Cite

176

116

View full text Add to dashboard Cite

Abstract-In 2011, the United Nations set key targets to reach by 2025 to reduce the risk of premature noncommunicable disease death by 25% by 2025. With cardiovascular disease being the largest contributor to global mortality, accounting for nearly half of the 36 million annual noncommunicable disease deaths, achieving the 2025 goal requires that cardiovascular disease and its risk factors be aggressively addressed. The Global Cardiovascular Disease Taskforce, comprising the World Heart Federation, American Heart Association, American College of Cardiology Foundation, European Heart Network, and European Society of Cardiology, with expanded representation from Asia, Africa, and Latin America, along with global cardiovascular disease experts, disseminates information and approaches to reach the United Nations 2025 targets. The writing committee, which reflects Global Cardiovascular Disease Taskforce membership, engaged the Institute for Health Metrics and Evaluation, University of Washington, to develop region-specific estimates of premature cardiovascular mortality in 2025 based on various scenarios. Results show that >5 million premature CVD deaths among men and 2.8 million among women are projected worldwide by 2025, which can be reduced to 3.5 million and 2.2 million, respectively, if risk factor targets for blood pressure, tobacco use, diabetes mellitus, and obesity are achieved. However, global risk factor targets have various effects, depending on region. For most regions, United Nations targets for reducing systolic blood pressure and tobacco use have more substantial effects on future scenarios compared with maintaining current levels of body mass index and fasting plasma glucose. However, preventing increases in body mass index has the largest effect in some high-income countries. An approach achieving reductions in multiple risk factors has the largest impact for almost all regions. Achieving these goals can be accomplished only if countries set priorities, implement cost-effective population wide strategies, and collaborate in publicprivate partnerships across multiple sectors. (Circulation. 2016;133:e674-e690.

show abstract

mentioning

confidence: 99%

The Heart of 25 by 25: Achieving the Goal of Reducing Global and Regional Premature Deaths From Cardiovascular Diseases and Stroke

Sacco¹,

Roth²,

Reddy³

et al. 2016

Circulation

Self Cite

176

116

View full text Add to dashboard Cite

show abstract

“…Improving or maintaining healthy functions of endothelial cells and their mediators has been shown to prolong life (Gielen et al, 2008;Green et al, 2008;Schächinger et al, 2000). Fortunately, the World Health Organization, local governments, and medical societies have recognized the importance of the preventive potential of physical activity and are actively promoting its use (Exercise Medicine Initiative, 2014;Haskell et al, 2007;Swedish National Institute of Public Health, 2010;Thompson et al, 2003;Zoghbi et al, 2014), including different recommendations by the World Health Organization for all age groups, including children and the elderly (WHO Recommendations, 2010).…”

Section: Practicing Health Awareness: Return Of Investmentmentioning

confidence: 99%

Aging and endothelin: Determinants of disease

Barton

2014

Life Sciences

View full text Add to dashboard Cite

Since the beginning of the 20th century human life expectancy has doubled to more than 80 years, and growth and aging of the world population now represent major challenges for healthcare providers, political decision makers, and societies. Cellular senescence is associated with a general, pro-inflammatory state, which represents the common denominator between aging and chronic diseases and their progression. Approaches to interfere with these changes and to allow healthy aging involve modulation of the cellular activity of modifiable molecular mediators (MMMs), such as signaling molecules and growth factors. ET-1 - the biologically predominant member of the endothelin peptide family - is an endothelial cell-derived peptide with a wide variety of developmental and physiological functions, which include embryogenesis, nociception, and natriuresis. In addition, ET-1 is a cytokine-like, multifunctional peptide with pro-inflammatory, mitogenic, and vasoconstrictor properties. If produced in excess amounts ET-1 promotes disease - mainly via activation of its ETA receptor. Because of its multiple disease-promoting functions ET-1 represents an ideal target MMM. Preclinical studies targeting either activity or production of ET-1 - utilizing ERAs, ARBs, or ACEIs, respectively - have demonstrated that partial regression of aging-associated changes in vasculature and kidney is possible. In this article I will review the molecular regulation of ET-1 and its role in the physiology of vascular homeostasis, aging, and cellular senescence. The clinical implications of activators of ET-1 overproduction, modalities for delaying or reversing aging-related cellular changes, as well as interventions to promote healthy aging and early disease prevention - particularly physical activity - are discussed.

show abstract

“…Stroke is the leading cause of disability in the Asian population. 1,2 It becomes important health problem for Bangladesh as more than 25% of its population live below the poverty line. 3 A large number of preventable deaths in Bangladesh occur due to stroke.…”

Section: Introductionmentioning

confidence: 99%

Knowledge of stroke risk factors among the patients with previous stroke or transient ischemic attack in a tertiary care hospital of Bangladesh

et al. 2020

View full text Add to dashboard Cite

Background: Patients of stroke or transient ischaemic attacks (TIA) are at risk of further stroke. Our objective was to study patients admitted with stroke/TIA regarding their knowledge about risk factors for having anew event of stroke/TIA, possible associations between patient characteristics and patients’ knowledge about risk factors, and patients’ knowledge about their preventive treatment for stroke/TIA. Methods: A questionnaire was used for 200 patients with stroke/TIA diagnoses. We asked 13 questions about diseases/conditions and lifestyle factors known to be risk factors and four questions regarding other diseases/ conditions (“distractors”). Additional questions concerned with the patients’ social and functional status and their drug use were asked. Categorical variables were analyzed using chi square test, while one-way analysis of variance and univariate analysis of variance were used for continuous variables. Logistic regression was employed to describe risk. A p value of, p < 0.05 was considered statistically significant. Results: The risk factors that were most often identified by the patients were Diabetes(75.9%), hypertension(83.3%), previous stroke or TIA(81.5%), smoking (85.2%), regular exercise(75.9%), older age(83.3%), overweight (75.9%) and patients with ischemic heart disease (70.4%). Atrial fibrillation and carotid stenosis were identified by less than 50% of the patients. 44.5% of the patients could identify 10 or more stroke/TIA risk factors. We observed that higher age, having a diagnosis of cerebral infarction/TIA, patients residing in urban area, high income group, businessman/retired service holder, family history of cardiovascular disease, past history of stroke / TIA were related to better knowledge of stroke/TIA risk factors. Anticoagulants and antiplatelets are important drugs for stroke/TIA prevention but only 20(9.3%) of the patients who reported anticoagulants and 76(35.2%) of the patients taking these drugs marked them as intended for prevention. Conclusion: Knowledge about diabetes, hypertension and smoking as risk factors was good, and patients who suffered from atrial fibrillation or carotid stenosis seemed to be less informed about these conditions as risk factors. The knowledge level was low regarding the use of anticoagulants and antiplatelets for stroke/TIA prevention. Better patient educational strategies for stroke/TIA patients should be developed. Furthermore, individuals with less knowledge should be given special consideration when developing strategies and programmes thus improving awareness of stroke risk factors. Birdem Med J 2021; 11(1): 22-29

show abstract

Sustainable Development Goals and the Future of Cardiovascular Health: A Statement From the Global Cardiovascular Disease Taskforce

Cited by 35 publications

References 3 publications

The Heart of 25 by 25: Achieving the Goal of Reducing Global and Regional Premature Deaths From Cardiovascular Diseases and Stroke

The Heart of 25 by 25: Achieving the Goal of Reducing Global and Regional Premature Deaths From Cardiovascular Diseases and Stroke

Aging and endothelin: Determinants of disease

Knowledge of stroke risk factors among the patients with previous stroke or transient ischemic attack in a tertiary care hospital of Bangladesh

Contact Info

Product

Resources

About